Design, Synthesis and Biological Activities of New Pyrazole Derivatives Possessing Both Coxib and Combretastatins Pharmacophores

Chem Biodivers. 2019 Jun;16(6):e1900108. doi: 10.1002/cbdv.201900108. Epub 2019 May 20.

Abstract

In our efforts to discover novel multi-target agents having better antitumor activities than celecoxib, 21 new aryl-substituted pyrazole derivatives possessing cis-diphenylethylene scaffold were mostly synthesized by a one-pot approach to ethyl 1,4,5-triaryl-1H-pyrazole-3-carboxylates via an improved Claisen condensation - Knorr reaction sequence. The cytotoxic effects of these compounds against three human cancer cell lines HT-29, Hep-G2, MCF-7 as well as their inhibition of NO production were studied. Results showed that incorporation of the important pharmacophoric groups of two original molecules celecoxib and combretastatin A-4 in a single molecule plays an important role in determining a better biological activities of the new coxib-hybrided compounds.

Keywords: COX-2; celecoxib; combretastatin; cytotoxicity; hybrid compounds; multi-target agents; synthesis design.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Bibenzyls / chemistry*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cyclooxygenase 2 Inhibitors / chemistry*
  • Drug Design*
  • Drug Screening Assays, Antitumor
  • Humans
  • Lipopolysaccharides / pharmacology
  • Macrophages / cytology
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Mice
  • Nitric Oxide / metabolism
  • Pyrazoles / chemical synthesis
  • Pyrazoles / chemistry*
  • Pyrazoles / pharmacology
  • RAW 264.7 Cells

Substances

  • Antineoplastic Agents
  • Bibenzyls
  • Cyclooxygenase 2 Inhibitors
  • Lipopolysaccharides
  • Pyrazoles
  • Nitric Oxide
  • combretastatin